Overview

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-10-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Abiraterone Acetate
Olaparib